Craft

Bluebird Bio

Stock Price

$1.4

2024-03-18

Market Capitalization

$277.5 M

2024-03-18

Revenue

$3.6 M

FY, 2022

Bluebird Bio Summary

Company Summary

Overview
Bluebird Bio is a developer of gene therapies for severe genetic diseases. It works on ZYNTEGLO (betibeglogene autotemcel) program, gene therapy for people with β-thalassemia who require regular red blood cell transfusions, and SKYSONA (elivaldogene autotemcel) program, therapy that slows the progression of neurologic dysfunction in children with cerebral adrenoleukodystrophy. The company also develops lovotibeglogene autotemcel (lovo-cel) as a one-time treatment for patients with sickle cell disease.
Type
Public
Status
Active
Founded
1992
HQ
Somerville, MA, US | view all locations
Website
https://www.bluebirdbio.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Andrew Obenshain

    Andrew Obenshain, Chief Executive Officer and Director

  • Tom Klima

    Tom Klima, Chief Commercial & Operating Officer

  • Andrea Walton

    Andrea Walton, Chief People Officer

  • Rich Colvin

    Rich Colvin, Chief Medical Officer

Operating MetricsView all

Patents and Patent Applications

1.2K
4.1%

FY, 2020

LocationsView all

1 location detected

  • Somerville, MA HQ

    United States

    455 Grand Union Blvd

Bluebird Bio Financials

Summary Financials

Revenue (Q3, 2023)
$12.4M
Gross profit (Q3, 2023)
$1.4M
Net income (Q3, 2023)
($71.7M)
Cash (Q3, 2023)
$165.3M
EBIT (Q3, 2023)
($84.7M)
Enterprise value
$415.9M

Footer menu